IC
BBIO icon

Ikarian Capital’s BridgeBio Pharma BBIO Stock Holding History

Ikarian Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-150,000
Closed -$2.58M – 149
2023
Q2 		$2.58M Buy
+150,000
New +$2.26M 0.41% 56
2022
Q1 		– Sell
-909,700
Closed -$15.2M – 202
2021
Q4 		$15.2M Buy
+909,700
New +$38.5M 2.26% 11

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's BBIO Position: Q1 2026 in Review

Ikarian Capital opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 160,120 shares worth $11.9M. The stake represents 0.97% of the portfolio and ranks #25 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in BBIO as recently as Q3 2025.

Ikarian Capital first reported a position in BBIO in Q1 2020 and has held it in 13 quarters since. The position peaked at $19.1M in Q4 2023. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Ikarian Capital held 160,120 shares of BridgeBio Pharma worth $11.9M as of Q1 2026.
  • BridgeBio Pharma was a new Ikarian Capital position in Q1 2026.
  • BridgeBio Pharma made up 0.97% of Ikarian Capital's portfolio in Q1 2026, its #25 holding.
  • Ikarian Capital first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 13 quarters since.
  • Ikarian Capital's BridgeBio Pharma position peaked at $19.1M in Q4 2023.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.